Progress of donor selection of haploidentical hematopoietic stem cell transplantation
10.3760/cma.j.cn115356-20190903-00173
- VernacularTitle:单倍体造血干细胞移植供者选择研究进展
- Author:
Yuan FENG
1
;
Jianyong LI
;
Kourong MIAO
Author Information
1. 南京医科大学第一附属医院 江苏省人民医院血液科 210029
- From:
Journal of Leukemia & Lymphoma
2020;29(6):374-377
- CountryChina
- Language:Chinese
-
Abstract:
Haploidentical hematopoietic stem cell transplantation (HID-HSCT) is increasingly used worldwide as an important treatment for hematopoietic diseases. Thanks to the improvements in new treatment regimens and drugs, more patients with hematopoietic disorders can benefit from it. Selecting the appropriate donor is good to optimize clinical outcomes. Many factors need to be taken into consideration when choosing the optimum donor, such as donor-specific antibodies, donor age, genetic relationship, gender and ABO compatibility, human lymphocyte antigen (HLA) mismatch, natural killer cell alloreactivity, and serum status of donor cytomegalovirus. This article reviews the new progress of donor selection of HID-HSCT.
